Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a blood test catch lymphoma relapse before scans do?

NCT ID NCT07878351

Diagnosis Sponsor: Peking University People's Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Oct 16, 2026 · Last updated Oct 16, 2026

Summary

Researchers are studying whether a blood test that detects tiny fragments of tumor DNA can track how well treatment works in people with diffuse large B-cell lymphoma or high-grade B-cell lymphoma. About 100 adults receiving standard first-line chemotherapy will give blood samples before, during, and after treatment. The study will check whether tumor DNA levels about eight weeks after treatment relate to how long patients stay cancer-free, and whether the test adds information beyond PET/CT scans.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If the blood test proves reliable, doctors could one day use it to spot leftover lymphoma sooner than scans and tailor follow-up care to each patient.
What could go wrong
This is an observational study of about 100 people at one point in treatment, so it cannot prove the test changes outcomes. ctDNA results may miss residual disease or give false alarms, and findings may not apply to other lymphoma types or treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Aug 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Newly diagnosed diffuse large B cell lymphoma (DLBCL), or high-grade B-cell lymphoma (HGBL).

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years, either sex. * Histopathologically confirmed diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). * Planned to receive standard immunochemotherapy including at least CD20 monoclonal antibody and anthracycline, such as Pola-RCHP, R-CHOP, or R-DA-EPOCH. * No maintenance therapy planned after completion of first-line treatment. * Written informed consent obtained. Exclusion Criteria: * DLBCL/HGBL transformed from indolent B-cell lymphoproliferative disorders. * HIV-positive large B-cell lymphoma. * Prior chemotherapy, targeted therapy, or immunotherapy for large B-cell lymphoma. * Investigator-assessed ineligibility for this study. * Concomitant other malignancies.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diffuse large B cell lymphoma (DLBCL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma high grade B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diffuse large B cell lymphoma (DLBCL) High grade B cell lymphoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Beijing TongRen Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100041, China

  • Peking University People's Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100044, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.